Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRN330 Plus Irinotecan in Metastatic Colorectal Cancer
NCT00838578Phase 2Terminated
- Sponsor
- Kyowa Kirin
- Start
- Mar 2009
- Primary completion
- Jul 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KRN330 in metastatic colorectal cancer (mCRC), sponsored by Kyowa Kirin. Primary endpoints: Number of Participants With Serious and Other (Non-Serious) Adverse Events up to 100 months and Response Rate. Started Mar 2009; status: terminated.
02
Drugs
KRN330
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00838578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00838578.